Osteoporosis is represented by loss of bone mass with consequent bone fragility and increased risk of fractures. Current treatment options include several classes of drugs and adjuvant use of vitamin D and calcium. The aim of this review is to study whether vitamin K2 could be of use to the actual treatment schemes as it is directly implicated in the normal metabolism of bone tissue. After consulting the current literature, we have found that vitamin K2 is able to reduce the risk of fracture in osteoporotic patients, increase osteocalcin and diminish levels of undercarboxylated osteocalcin. In conclusion, vitamin K2 has the capability of improving the outcome and evolution of osteoporosis with minimal to no adverse effects and possibly achieving higher treatment compliance.
展开▼
